TX-MAVENIR
12.4.2022 09:02:15 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced the collaboration with Aspire Technology (Aspire), a specialized Network Solutions developer and System Integrator, to accelerate the market availability of O-RAN split 7.2 compliant Remote Radiohead Units (RRUs) leveraging Aspire’s Open Networks Lab in Europe.
Communication Service Providers (CSPs) demand for integrated high performing Open Radio Access Network (Open RAN) solutions based on Mavenir O-RAN compliant cloud-native Centralized Unit (CU) and Distributed Unit (DU) RAN software stacks is growing fast, fueled by modernization and coverage expansion projects, as well as private networks and indoor projects.
The number of O-RAN compliant RRUs from partners globally is also growing with sophisticated products across the different radio technologies, including Massive MIMO (mMIMO) and millimeter Wave (mmWave).
Mavenir and Aspire will be leveraging Aspire’s Open Networks Lab in Dublin for third-party RRU integration and testing. Furthermore, RRU vendors will be able to engage directly with Aspire and fast-track the integration and testing of new O-RAN compliant radios and frequency variants with Mavenir CU/DU software.
This collaboration will benefit not only RRU vendors, but also CSPs by expanding the offering of innovative and high-performing solutions supporting a wide number of use cases.
“This partnership greatly enhances the capacity to integrate and test RRUs with Mavenir’s CU/CU for 4G and 5G,” said Puneet Sethi, SVP/GM RAN Business for Mavenir. “Open RAN has accelerated to a point that we need to continuously innovate to be ahead of demand, including go-to-market models. Our RRU partners want to get their newest products available for deployment, and CSPs want to take full advantage of a fast-paced ecosystem minimizing integration and testing effort. We are continuously expanding our partner eco-systems for RRU integration to respond to the evolving market needs with specialized high-quality services and fast turnaround.”
Declan Friel, CTO, Aspire said; “We are delighted to extend our relationship with Mavenir. Aspire’s heritage in software engineering and testing of complex radio products carried over into Open RAN, combined with global CSP experience through design, optimization and support of live networks, uniquely positions us to accelerate the availability of new ORAN compliant solutions for wide market adoption. As a European-based independent company, and with our Open Networks Lab in Ireland today supporting a number of global clients and partners, our focus has been to accelerate the ORAN ecosystem development and to support CSPs. This will allow them to fully realize the benefits of Telco Cloud, Service Management & Orchestration and Open RAN, in terms of flexibility, performance and cost.”
About Mavenir:
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
About Aspire:
Aspire Technology is a leading Specialized System Integrator with a long history and experience in fixed and mobile networks, and Open RAN since its early days. Aspire’s clients are spread around the Globe and benefit from their advanced services and software automation solutions. The Aspire Open RAN Lab enables technology partners and communications service providers to fasttrack development, integration, benchmarking, testing and deployment of Open RAN based networks and solutions. Aspire has been actively contributing to acceleration of time to market, reduction of deployment cost and improvement of multivendor interoperability and network performance. www.aspiretechnology.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220412005063/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
